SC0191 + 5-fluorouracil + leucovorin

SC0191 + 5-fluorouracil + leucovorin is an investigational combination therapy under clinical evaluation for advanced solid tumors, including metastatic colorectal cancer. The regimen combines three agents: - **SC0191**, a novel small molecule inhibitor of Wee1 kinase, which disrupts the G2/M cell cycle checkpoint in TP53-mutant tumor cells, promoting mitotic entry and apoptosis in the presence of DNA damage[5]. - **5-fluorouracil (5-FU)**, a pyrimidine analog antimetabolite that inhibits thymidylate synthase and interferes with DNA synthesis. - **Leucovorin (folinic acid)**, which enhances the binding of 5-FU to thymidylate synthase, increasing its cytotoxicity. This combination is being studied for its safety and preliminary efficacy in patients with advanced or metastatic colorectal cancer who have progressed after standard therapies[3][6]. The approach leverages synergistic effects between cell cycle checkpoint inhibition (via Wee1 blockade) and DNA-damaging chemotherapy.

Other names

SC0191 + 5-FU + LVSC0191 plus 5-fluorouracil and leucovorinSC-0191 plus 5-fluorouracil and leucovorinSC 0191 plus 5-fluorouracil and leucovorin